Wang, B. and Kesselheim, A.S., “Characteristics of Efficacy Evidence Supporting Approval of Supplemental Indications for Prescription Drugs in United States, 2005-14: Systematic Review,” British Medical Journal, 351 (2015): h4679; M. Dhodapkar, et al., “Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019,” JAMA Network Open 4, no. 6 (June 10, 2021): e2113224.Google ScholarPubMed

Berndt, E.R., Cockburn, I.M., Grépin, K.A., “The Impact of Incremental Innovation in Biopharmaceuticals,” PharmacoEconomics 24, no. 2 (December 1, 2006): 69–86; J.A. DiMasi, “Innovating by Developing New Uses of Already-Approved Drugs: Trends in the Marketing Approval of Supplemental Indications.” Clinical Therapeutics 35, no. 6 (June 1, 2013): 808–18; J. Cohen, A. Wilson, L. Faden, “Off-Label Use Reimbursement,” Food and Drug Law Journal 64, no. 2 (2009): 391–403.Google ScholarPubMed

21 C.F.R. § 314.50 (2023).CrossRefGoogle Scholar

Moffitt, S.L., “Promoting Agency Reputation through Public Advice: Advisory Committee Use in the FDA,” The Journal of Politics 72, no. 3 (July 2010): 880–93.CrossRefGoogle Scholar

Smith, J.F. et al., “FDA Advisory Committee Meeting Outcomes,” Nature Reviews Drug Discovery 11, no. 7 (2012): 513–14; A.D. Zhang, J.L. Schwartz, J.S. Ross, “Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008–2015,” The Milbank Quarterly 97, no. 3 (2019): 796–819; C.J.R. Daval, A. Sarpatwari, A.S. Kesselheim, “Unwanted Advice? Frequency, Characteristics, And Outcomes of Negative Advisory Committee Votes For FDA-Approved Drugs,” Health Affairs 41, no. 5 (May 2022): 713–21; C.J.R. Daval, et al., “Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010–2021,” JAMA Health Forum 4, no. 7 (July 7, 2023): e231718.Google ScholarPubMed

Gupta, R., et al., “During COVID-19, FDA’s Vaccine Advisory Committee Has Worked To Boost Public Trust – It Can Still Do More,” Health Affairs Forefront, https://www.healthaffairs.org/do/10.1377/forefront.20210225.712221/full/ (last visited April 1, 2024).Google Scholar

“Advisory Committees,” US Food and Drug Administration, https://www.fda.gov/advisory-committees (last visited April 1, 2024).Google Scholar

“Drugs@FDA: FDA-Approved Drugs,” US Food and Drug Administration, https://www.accessdata.fda.gov/scripts/cder/daf/ (last visited April 1, 2024).Google Scholar

“Search Orphan Drug Designations and Approvals,” US Food and Drug Administration, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (last visited April 1, 2024).Google Scholar

Glaser, B.G., “The Constant Comparative Method of Qualitative Analysis,” Social Problems 12, no. 4 (April 1965): 436–45; H. Boejie, “A Purposeful Approach to the Constant Comparative Method in the Analysis of Qualitative Interviews,” Quality & Quantity 36 (2002): 391–409; E.H. Bradley, L.A. Curry, K.J. Devers, “Qualitative Data Analysis for Health Services Research: Developing Taxonomy, Themes, and Theory,” Health Services Research 42, no. 4 (August 2007): 1758–72.Google Scholar

Ross, J.S., Dzara, K., Downing, N.S., “Efficacy and Safety Concerns Are Important Reasons Why the FDA Requires Multiple Reviews Before Approval of New Drugs,” Health Affairs 34, no. 4 (2015): 681–88; L.V. Sacks, et al., “Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012,” JAMA 311, no. 4 (2014): 378–84.Google ScholarPubMed

Janiaud, P., et al., “US Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013–2018,” Annals of Internal Medicine 174, no. 11 (November 16, 2021): 1603–11.Google ScholarPubMed

Turner, E H., et al., “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy,” New England Journal of Medicine 358, no. 3 (2008): 252–60; K. Dwan, et al., “Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias,” PLoS ONE 3, no. 8 (2008): e3081; K. Lee, P. Bacchetti, I. Sim, “Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis,” PLoS Medicine 5, no. 9 (2008): 1348–55.CrossRefGoogle ScholarPubMed

“Guidance for FDA Advisory Committee Members and FDA Staff: Voting Procedures for Advisory Committee Meetings,” US Food and Drug Administration, https://www.fda.gov/media/75426/download (last visited April 1, 2024); Broniatowski, D.A. and Magee, C.L.. “Does Seating Location Impact Voting Behavior on Food and Drug Administration Advisory Committees?,” American Journal of Therapeutics 20, no. 5 (2013): 502–6; M. Newham and R. Midjord, “Herd Behavior in FDA Committees: A Structural Approach,” SSRN Electronic Journal, DIW Berlin Discussion Paper No. 1744 (2018), https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3208645.CrossRefGoogle ScholarPubMed

Urfalino, P. and Costa, P., “Secret-Public Voting in FDA Advisory Committees,” in Secrecy and Publicity in Votes and Debates, ed. by Elster, Jon, 1st ed., (Cambridge University Press, 2015): at 165–95.Google Scholar

See Urfalino, supra note 14.Google Scholar

See 21 C.F.R., supra note 3.Google Scholar

See Zhang, supra note 4; Daval, supra note 4.Google Scholar